Skip to content
lifestyle.theroguemag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Intellia Therapeutics, Inc.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
September 4, 2026
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
September 4, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
August 6, 2026
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
July 30, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
June 1, 2026
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
May 24, 2026
Intellia Therapeutics to Participate in Upcoming Investor Conferences
May 22, 2026
1
2
Next Page
→